FL is a slow-growing and incurable blood cancer that starts in the lymphatic system, which is a system of lymph nodes found throughout the body, including the neck, underarms, chest, abdomen and groin/pelvis. While FL can occur at any age, it is most frequently diagnosed among people aged 55-64, with a median age of 63. Of the estimated 74,000 individuals diagnosed with non-Hodgkin lymphoma in the United States each year, FL accounts for approximately 20% of all cases, or about 14,800 individuals.

It’s important for patients and doctors to remember that cancer care should not be put by the wayside due to COVID-19. By having routine and open conversations with healthcare providers via telemedicine and select in-person visits, patients can help to support their own improved health outcomes. There is also new hope as treatment advances give patients with FL, and the doctors who treat them, new, convenient options to help fight this debilitating cancer.

With the FDA’s recent accelerated approval of TAZVERIK (tazemetostat) for the treatment of adults with relapsed or refractory follicular lymphoma who have received at least 2 prior systemic therapies, FL patients have a new oral treatment option to discuss with their physicians. This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). 

Media Contact
John Mathews
Journal Manager
Journal of Phlebology and Lymphology
Email: phlebology@eclinicalsci.com